{
    "SPADE_UN_13506": {
        "Clinical Information": [],
        "Patent Information": [],
        "Sequence Information": {
            "SPADE ID": "SPADE_UN_13506",
            "Peptide Name": "EKL1C",
            "Source": "Synthetic construct",
            "Family": "Not found",
            "Gene": "Not found",
            "Sequence": "NVTFLDLEYEMKKLEEAIKKLEESYIDLKELGTYEYGSGC",
            "Sequence Length": 40,
            "UniProt Entry": "No entry found",
            "Protein Existence": "Not found",
            "Biological Activity": [
                "Antimicrobial",
                "Antiviral(SARS-CoV-2)"
            ],
            "Target Organism": "[Ref.35087243]Virus:SARS-CoV-2 Omicron:inhibition of cell-cell fusion in Calu-3 cells(IC50=12.18 nM);inhibition of cell-cell infusion in Caco2 cells(IC50=5.52 nM);inhibition of infection(Pseudovirus)(IC50=26.14 nM);inhibition of infection(Authentic)(IC50=182.2 nM);SARS-CoV-2 Delta:inhibition of cell-cell fusion(IC50=14.42 nM);inhibition of infection(Pseudovirus)(IC50=31.99 nM);SARS-CoV-2 D614G:inhibition of cell-cell fusion(IC50=11.77 nM);inhibition of infection(Pseudovirus)(IC50=23.6 nM).[Ref.34367893]Virus:SARS-CoV-2:Inhibition of Pseudovirus(PsV) infection in Huh-7 cells(IC50=0.045±0.006 μmol/L),Inhibition of Pseudovirus(PsV) infection in 293T/ACE2 cells(IC50=0.037±0.009 μmol/L),Inhibition of Pseudovirus(PsV) infection in Caco-2 cells(IC50=0.040±0.005 μmol/L),inhibition of cell-cell fusion(IC50=0.008±0.001 μmol/L);inhibited authentic SARS-CoV-2 infection in Vero E6 cells(IC50=0.003±0.001 μmol/L);SARS-CoV-2 variants(inhibition of Pseudovirus(PsV) infection):V341L(IC50=0.047±0.013 μmol/L);F342L(IC50=0.026±0.007 μmol/L);V367F(IC50=0.066±0.012 μmol/L);R408I(IC50=0.148±0.012 μmol/L);N435D(IC50=0.135±0.013 μmol/L);G476S(IC50=0.065±0.008 μmol/L);V483A(IC50=0.078±0.011 μmol/L);N501Y(IC50=0.069±0.006 μmol/L);D614G(IC50=0.104±0.010 μmol/L);12 mutations(P.1)(IC50=0.046±0.006 μmol/L);K417N-E484K-N501Y(IC50=0.113±0.013 μmol/L);8 mutations(B.1.1.7)(IC50=0.120±0.009 μmol/L);wide type(IC50=0.049±0.007 μmol/L);inhibition of multiple HCoV Pseudovirus:SARS-CoV (IC50=0.076±0.014 μmol/L), MERS-CoV(IC50=0.048±0.006 μmol/L), HCoV-OC43(IC50=0.668±0.081 μmol/L), HCoV-NL63(IC50=0.035±0.003 μmol/L), SARSr-CoV-WIV1(IC50=0.218±0.013 μmol/L), and HCoV-Rs3367 (IC50=0.046±0.003 μmol/L),inhibition of authentic HCoV-OC43 infection in RD cells (IC50=0.281±0.018 μmol/L).",
            "Hemolytic Activity": "No hemolysis information or data found in the reference(s) presented in this entry",
            "Cytotoxicity": "[Ref.34367893]Huh-7 cells:CC50=10 μmol/L;Caco-2 cells:CC50=13.81 μmol/L;293T/ACE2 cells:CC50=8.49 μmol/L.",
            "Binding Target": "liposomes",
            "Linear/Cyclic": "Linear",
            "N-terminal Modification": "Free",
            "C-terminal Modification": "Chol",
            "Stereochemistry": "L",
            "Structure Description": "Not found",
            "Formula": "C211H328N46O70S2",
            "Mass": 4693.26,
            "PI": 4.39,
            "Net Charge": -5,
            "Hydrophobicity": -0.56,
            "Half Life": "Mammalian:1.4 hourYeast:3 minE.coli:>10 hour",
            "Comments": "EKL1C is a Peptide-based pan-CoV fusion inhibitor,targets a highly conserved target site in HR1 domains in S protein of HCoVs.",
            "Literature": [
                {
                    "Title": "Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant.",
                    "Pubmed ID": "35087243",
                    "Reference": "Cell Res. 2022 Apr;32(4)404-406.",
                    "Author": "Xia S, Chan JF, Wang L, Jiao F, Chik KK, Chu H, Lan Q, Xu W, Wang Q, Wang C, Yuen KY, Lu L, Jiang S.",
                    "URL": "http://www.ncbi.nlm.nih.gov/pubmed/?term=35087243"
                },
                {
                    "Title": "A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases.",
                    "Pubmed ID": "34367893",
                    "Reference": "Acta Pharm Sin B. 2021 Aug 2.",
                    "Author": "Zhou J, Xu W, Liu Z, Wang C, Xia S, Lan Q, Cai Y, Su S, Pu J, Xing L, Xie Y, Lu L, Jiang S, Wang Q.",
                    "URL": "http://www.ncbi.nlm.nih.gov/pubmed/?term=34367893"
                }
            ],
            "Frequent Amino Acids": "ELK",
            "Absent Amino Acids": "HOPQRUW",
            "Basic Residues": 5,
            "Acidic Residues": 10,
            "Hydrophobic Residues": 16,
            "Polar Residues": 17,
            "Positive Residues": 5,
            "Negative Residues": 10,
            "Similar Sequences": [
                {
                    "SPADE_ID": "SPADE_UN_13502",
                    "Similarity": 1.0,
                    "Sequence": "SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKEL"
                },
                {
                    "SPADE_ID": "SPADE_UN_13508",
                    "Similarity": 1.0,
                    "Sequence": "NVTFLDLEYEMKKLEEAIKKLEESYIDLKELGTYEY"
                },
                {
                    "SPADE_ID": "SPADE_UN_13511",
                    "Similarity": 1.0,
                    "Sequence": "SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGTYEYYVKWGSGC"
                }
            ]
        }
    }
}